Form 4: Regeneron's President and CSO, George Yancopoulos, Executes Stock Sales Under 10b5-1 Plan

George Yancopoulos, President and CSO of Regeneron Pharmaceuticals, sold shares of common stock on May 16, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• On May 16, 2024, George Yancopoulos, the President and CSO of Regeneron Pharmaceuticals, sold shares of the company's common stock.
• The sales were executed under a pre-arranged trading plan that complies with Rule 10b5-1(c), which was adopted on February 14, 2024.
• The transactions involved multiple sales at varying prices, ranging from $967.13 to $978.75 per share.
• A total of 50,900 shares were sold on May 16, 2024.
• Following the reported transactions, Yancopoulos directly owns 786,383 shares of Regeneron common stock.
• He also indirectly owns shares through a 401(k) plan (5,903 shares), trusts for children (180,000 shares), a 2022 GRAT II (158,410 shares), and directly for his children (18,148 shares).

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating insider stock sales under a pre-arranged plan. It doesn't inherently convey positive or negative sentiment, but rather provides factual information about the transactions.

Positives

• The sales were executed under a pre-arranged 10b5-1 trading plan, which is a legal and transparent way for insiders to sell shares.

Industry Context

Insider sales are a common occurrence in publicly traded companies, and the use of 10b5-1 plans allows insiders to sell shares without being accused of trading on non-public information. Investors often monitor these transactions for insights into management's perspective on the company's value.

Comparison to Industry Standards

• Executive stock sales are a normal part of compensation and portfolio management in publicly traded companies like Regeneron.
• Companies such as Amgen, Gilead Sciences, and Biogen also see regular insider trading activity.
• The use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations, similar to what executives at Pfizer or Merck do.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.
• The transactions do not directly impact employees, customers, suppliers, or creditors.

Key Dates